Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2006-01-24
2006-01-24
Saidha, Tekchand (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S197000, C435S252300, C435S320100, C536S023200, C424S094600
Reexamination Certificate
active
06989261
ABSTRACT:
The invention provides a butyrylcholinesterase variant having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acid. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition with the invention variant.
REFERENCES:
patent: 5215909 (1993-06-01), Soreq
patent: 5264563 (1993-11-01), Huse
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5460959 (1995-10-01), Mulligan et al.
patent: 5506125 (1996-04-01), McCabe et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5620896 (1997-04-01), Herrmann et al.
patent: 5643578 (1997-07-01), Robinson et al.
patent: 5656465 (1997-08-01), Panicali et al.
patent: 5830721 (1998-11-01), Stemmer et al.
patent: 5891725 (1999-04-01), Soreq et al.
patent: 6001625 (1999-12-01), Broomfield et al.
patent: 2001/0014476 (2001-08-01), Crouzet et al.
patent: 2002/0119489 (2002-08-01), Lockridge
patent: 0 779 365 (1997-06-01), None
patent: WO 97/09441 (1997-03-01), None
patent: WO 97/10343 (1997-03-01), None
patent: WO 99/66072 (1999-12-01), None
Abremski, et al., “Studies on the Properties of P1 Site-Specific Recombination: Evidence for Topologically Unlinked Products Following Recombination.” Cell; 1983, vol. 32: 1301-1311.
Ashani, Y., “Prospective of Human Butyrylcholinesterase as a Detoxifying Antidote and Potential Regulator of Controlled-Release Drugs.” Drug Development Research; 2000, vol. 50: 298-308 (XP009008406).
Bethke, et al., “Segmental Genomic Replacement by Cre-Mediated Recombination: Genotoxic Stress Activation of the P53 Promoter in Single-Copy Transformants.” Nucl. Acids Res.; 1997, vol. 25: 2828-2834.
Blong, et al., “Tetramerization Domain of Human Butyrylcholinesterase Is at the C-Terminus.” Biochem. J.; 1997, vol. 327: 747-757.
Crameri, et al., “DNA Shuffling of a Family of Genes from Diverse Species Accelerates Directed Evolution.” Nature; 1998, vol. 391:288-291.
Dymecki, et al., “Flp Recombinase Promotes Site-Specific DNA Recombination in Embryonic Stem Cells and Transgenic Mice.” Proc. Natl. Acad. Sci. USA; 1996, vol. 93:6191-6196.
Fukushige, et al., “Genomic Targeting with a Positive-SelectionLoxIntegration Vector Allows Highly Reproducible Gene Expression in Mammalian Cells.” Proc. Natl. Acad. Sci. USA; 1992, vol. 89:7905-7909.
Glaser, et al., “Antibody Engineering by Codon-Based Mutagenesis in a Filamentous Phage Vector System.” J. Immunology; 1992, vol. 149: 3903-3913.
Gorelick, “Enhancing Cocaine Metabolism with Butyrylcholinesterase as a Treatment Strategy.” Drug Alcohol Depend.; 1997, vol. 48: 159-165.
Harel, et al., “Conversion of Acetylcholinesterase to Butyrylcholinesterase: Modeling and Mutagenesis.” Proc. Natl. Acad. Science USA; 1992, vol. 89:10827-10831.
Hoess, et al., “The Role of the IoxP Spacer Region in P1 Site-Specific Recombination.” Nucl. Acids Res.; 1986, vol. 14: 2287-2300.
Kunkel, “Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection.” Proc. Natl. Acad. Sci. USA; 1985, vol. 82, 488-492.
Lockridge, et al., “A Single Amino Acid Substitution, Gly117His, Confers Phosphotriesterase (Organophosphorus Acid Anhydride Hydrolase) Activity on Human Butyrylcholinesterase.” Biochemistry; 1997, vol. 36: 786-795.
McTiernan, et al., “Brain cDNA Clone for Human Cholinesterase.” Proc. Natl. Acad. Sci. USA; 1987, vol. 84: 6682-6686.
Masson, et al., “Role of Aspartate 70 and Tryptophan 82 in Binding of Succinyldithiocholine to Human Butyrylcholinesterase.” Biochemistry; 1997, vol. 36: 2266-2277.
Mets, et al., “A Catalytic Antibody Against Cocaine Prevents Cocaine's Reinforcing and Toxic Effects in Rats.” Proc. Natl. Acad. Sci. USA; 1998, vol. 95:10176-10181.
Sauer, et al., “Site-Specific DNA Recombination in Mammalian Cells by the Cre Recombinase of Bacteriophage P1.” Proc. Natl. Acad. Sci. USA; 1998, vol. 85 5166-5170.
Schwarz, et al., “Engineering of Human Cholinesterases Explains and Predicts Diverse Consequences of Administration of Various Drugs and Poisons.” Pharmac. Ther.; 1995, vol. 67:283-322.
Soreq, et al., “Excavations into the Active-Site Gorge of Cholinesterases.” Trends Biochem. Science; 1992, vol. 17: 353-358.
Stemmer, “DNA Shuffling by Random Fragmentation and Reassembly:In vitroRecombination for Molecular Evolution.” Proc. Natl. Acad. Sci. USA; 1994, vol. 91: 10747-10751.
Sun, et al., “Re-engineering Butyrylcholinesterase as a Cocaine Hydrolase.” Molecular Pharmacology; 2002, vol. 62, No. 2: 220-224.
Sussman, et al., “Atomic Structure of Acetylcholinesterase FromTorpedo californica: A Prototypic Acetylcholine-Binding Protein.” Science; 1991, vol. 253: 872-879.
Tatusova, et al., “Blast 2 Sequences, a New Tool For Comparing Protein and Nucleotide Sequences.” FEMS Microbiol. Lett.; 1999, vol. 174: 247-250.
Watkins, et al., “Determination of the Relative Affinities of Antibody Fragments Expressed inEscherichia Coliby Enzyme-Linked Immunosorbent Assay.” Analy. Biochem.; 1997, vol. 253: 37-45.
Wu, et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues.” J. Mol. Biol.; 1999, vol. 294:151-162.
Wu, et al., “Stepwisein vitroAffinity Maturation of Vitaxin, an avβ3—Specific Humanized mAb.” Proc. Natl. Acad. Sci. USA; 1998, vol. 95: 6037-6042.
Xie, et al., “An Improved Cocaine Hydrolase: The A328Y Mutant of Human Butyrylcholinesterase Is 4-Fold More Efficient.” Molecular Pharmacology; 1999, vol. 55: 83-91 (XP002236142).
Pancook James D.
Watkins Jeffry D.
Davis Paula K.
Eli Lilly and Company
Saidha Tekchand
LandOfFree
Butyrylcholinesterase variant polypeptides with increased... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Butyrylcholinesterase variant polypeptides with increased..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Butyrylcholinesterase variant polypeptides with increased... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3545228